Clinical trials: Prostate Cancer With Intermediate Risk
Prostate Cancer
Hemiablative Focal Brachytherapy Pilot Study
Whole gland LDR brachytherapy has been a well established modality of treating low risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs.
- Trial name
- NCT02643511
- Testing
- Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- St George Hospital, Australia
Prostate Cancer
Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer
On the basis of the now consolidated literature and clinical experience of focal therapies, the execution of partial prostatectomy/hemiprostatectomy with robot-assisted laparoscopic technique can be proposed in a well-selected…
- Trial name
- RETURN (NCT05832736)
- Testing
- Robotic hemi-prostatectomy with urethral preservation
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Safety and Efficacy Evaluation of Transperineal Irreversible Electroporation (IRE) of Anterior Prostate Cancer
Most prostate cancer treatment research in the last decade has been focused on trying to improve quality of life, while maintaining a high level of cancer control.
- Trial name
- NCT05512663
- Testing
- Irreversible Electroporation (IRE)
- Volunteers
- 10 people
- Sponsor
- Jewish General Hospital
Prostate Cancer
Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy
As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after…
- Trial name
- AdRad (NCT00653848)
- Testing
- docetaxel
- Where
- Norway
- Volunteers
- 378 people
- Sponsor
- Scandinavian Prostate Cancer Group
Prostate Cancer
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
Despite recent advances in the treatment of Castrate-Resistant Prostate Cancer (CRPC), there remains an unmet medical need to identify and optimise additional treatment for those patients with early prostate cancer who are at…
- Trial name
- CaNCaP03 (NCT02324998)
- Testing
- Olaparib, Degarelix
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cancer Of Prostate
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment.
- Trial name
- NCT05361798
- Testing
- PDS01ADC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Stage I
Targeted Microwave Focal Therapy
Focal therapy (FT) for prostate cancer (PCa) is an interesting therapeutic option for localized disease with a favorable low- to intermediate-risk profile.
- Trial name
- NCT04627896
- Testing
- Katty focal therapy
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Prostate Cancer
Brachytherapy for Prostatic Carcinoma Patients
The goal of this clinical research study is to learn if a prostate implant (brachytherapy) can help to control intermediate risk prostate cancer. The safety of this procedure will also be studied.
- Trial name
- NCT00525720
- Testing
- Brachytherapy, Questionnaire
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes.
- Trial name
- NCT07801664
- Testing
- Androgen Deprivation Therapy (ADT), Radiotherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- NYU Langone Health
Prostate Cancer
Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients With Intermediate Risk Localized Prostate Cancer
The purpose of this research study is to collect information on a new treatment of prostate tissue participants with intermediate risk prostate cancer using a medical device called the Poseidon System.
- Trial name
- NCT04087980
- Testing
- Poseidon System
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Francis Medical Inc.
Prostate Adenocarcinoma
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the…
- Trial name
- LDR BURST (NCT07210502)
- Testing
- 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Neoplasm, Prostate
Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer
For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy and 21 Gy in 3 fractions, respectively.
- Trial name
- ADEBAR (NCT03322020)
- Testing
- Cyberknife boost 18 Gy, Cyberknife boost 21 Gy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Prostate Cancer
ABlative Radiotherapy (for) Unfavorable Prostate Tumors
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Trial name
- ABRUPT (NCT04831983)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milano Bicocca
Prostate Cancer
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer…
- Trial name
- ARN-509 (NCT03488810)
- Testing
- Radiation Therapy, Apalutamide, Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Vaccination in Prostate Cancer (VANCE)
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- NCT02390063
- Testing
- ChAdOx1.5T4, MVA.5T4, Cyclophosphamide
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Prostate Cancer, Cancer of the Prostate
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected…
- Trial name
- NCT05628363
- Testing
- Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II
High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer
This phase II trial studies how well high-intensity focused ultrasound works in treating participants with intermediate and high-risk prostate cancer.
- Conditions
- Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II, Prostate Cancer Stage III
- Trial name
- NCT03514927
- Testing
- Contrast-Enhanced Ultrasound, High-Intensity Focused Ultrasound, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Southern California
Prostate Cancer
Timing of HDR With EBRT in Localised Prostate Cancer,Toxicity and Quality of Life Assessment
TITLE Timing of HDR brachytherapy with EBRT in intermediate and high risk localised Prostate CAncer patients and its effects on Toxicity and Quality of life - randomised feasibility trial.
- Trial name
- THEPCA (NCT02618161)
- Testing
- HDR Brachytherapy, External beam Radiotherapy
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Mid and South Essex NHS Foundation Trust
Prostate Cancer
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as…
- Trial name
- SChLAP/IDC (NCT04176081)
- Testing
- Darolutamide, Degarelix, Radiation Therapy
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- University Health Network, Toronto